Platelet Count After Chemotherapy is a Predictor for Outcome for Ovarian Cancer Patients. (28th May 2015)

• Record Type: Journal Article
• Authors: Eggemann, H.; Ehricke, J.; Ignatov, T.; Fettke, F.; Semczuk, A.; Costa, S. D.; Ignatov, A.
• Is Part Of: Cancer investigation. Volume 33:Number 5(2015)
• Page Start: 193
• Page End: 196
• Publication Date: 2015-05-28
• Subjects: Cancer -- Periodicals; Oncology -- Periodicals; Medical Oncology -- Periodicals; Neoplasms -- Periodicals; 616.994
• DOI: 10.3109/07357907.2015.1020384
• Languages: English
• ISSNs: 0735-7907

Abstract

<abstract> <title> <x xml:space="preserve">Abstract</x> </title> <p>Elevated platelet count occasionally is associated with gynecologic malignancies. We investigated the level of platelet count in 450 patients with gynecologic tumors. Ovarian cancer patients have increased platelet count associated with the course of treatment and disease progression. In multivariate analysis, the decrease of platelet count less than 25% after chemotherapy was an unfavorable prognostic factor for PFS (HR, 1.948; 95% CI, 1.083–3.505; <italic>p</italic> = 0.026) and overall survival (HR, 2.093; 95% CI, 1.022–4.287; <italic>p</italic> = 0.043). An insufficient decrease of the platelet count increased the risk of recurrence. Thus platelet count could be used for monitoring the disease progression and to predict treatment response.</p> </abstract>